The authors report a case of a 69-year-old woman with multiple sclerosis treated with fingolimod for duration of over one year who subsequently developed cutaneous large B cell lymphoma. There are few reported cases of lymphoma associated with fingolimod treatment for multiple sclerosis, but rates are higher than expected in the general population. The authors hope to promote awareness of the potential risk of this medication so that more diligent disease surveillance can be performed by both prescribing practitioners of fingolimod and their patients who receive it.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.msard.2017.11.014 | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!